Adults with Metastatic Castration Resistant Prostate Cancer invited to be in a research study assessing the safety and efficacy of an investigational drug

UVA Tracking #
Principal Investigator
Michael Devitt
Milos Lesevic
Contact Phone
Official Trial Title
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in patients who have failed prior treatment with one androgen receptor targeting agent
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have metastatic castration-resistant prostate cancer (mCRPC). The study will have two groups of patients who will receive either VERU-111 or an active control (second, or alternative androgen receptor targeting agent). The group you are in will be selected at random.

Recruitment, treatment with the study medication and patient follow up during the study is expected to last up to approximately 22 months. The overall duration of your participation in the study will be determined by how well you tolerate the treatment and by whether your prostate cancer is stable or improving.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to
you or your insurance.

Additional information can be found here:


$50 stipend per visit Up to $175 for hotel, per night